WallStreetZenWallStreetZen

NASDAQ: BPMC
Blueprint Medicines Corp Earnings & Revenue

BPMC past revenue growth

How has BPMC's revenue growth performed historically?
Company
37.94%
Industry
89.98%
Market
18.88%
BPMC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BPMC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BPMC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BPMC earnings and revenue history

Current Revenue
$282.2M
Current Earnings
-$288.3M
Current Profit Margin
-102.2%

BPMC Return on Equity

Current Company
-120.7%
Current Industry
16.8%
Current Market
28.2%
BPMC's Return on Equity (-120.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BPMC announces earnings.

BPMC Return on Assets

Current Company
-26.8%
Current Industry
3.2%
BPMC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BPMC Return on Capital Employed

Current Company
-32.31%
Current Industry
-42.4%
BPMC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BPMC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BPMC$282.21M-$246.69M-$288.29M+44.82%N/A
IONS$776.62M-$254.76M-$384.77M+0.63%N/A
HALO$862.99M$495.45M$318.80M+37.13%+101.37%
JAZZ$3.84B$1.16B$330.79M+14.48%-8.51%
RVMD$4.57M-$477.95M-$484.27M-44.59%N/A

BPMC earnings dates

Next earnings date
Jul 31, 2024

Blueprint Medicines Earnings & Revenue FAQ

What were BPMC's earnings last quarter?

On Invalid Date, Blueprint Medicines (NASDAQ: BPMC) reported Q1 2024 earnings per share (EPS) of $1.45, up 167.44% year over year. Total Blueprint Medicines earnings for the quarter were $89.14 million. In the same quarter last year, Blueprint Medicines's earnings per share (EPS) was -$2.15.

If you're new to stock investing, here's how to buy Blueprint Medicines stock.

What was BPMC's earnings growth in the past year?

As of Q3 2024, Blueprint Medicines's earnings has grown year over year. Blueprint Medicines's earnings in the past year totalled -$288.29 million.

What is BPMC's earnings date?

Blueprint Medicines's earnings date is Invalid Date. Add BPMC to your watchlist to be reminded of BPMC's next earnings announcement.

What was BPMC's revenue last quarter?

On Invalid Date, Blueprint Medicines (NASDAQ: BPMC) reported Q1 2024 revenue of $96.12 million up 51.87% year over year. In the same quarter last year, Blueprint Medicines's revenue was $63.29 million.

What was BPMC's revenue growth in the past year?

As of Q3 2024, Blueprint Medicines's revenue has grown 37.94% year over year. This is 52.04 percentage points lower than the US Biotechnology industry revenue growth rate of 89.98%. Blueprint Medicines's revenue in the past year totalled $282.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.